Product Description
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Herpes Simplex
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04762511 |
NCT04762511 | P1 |
Terminated |
Herpes Simplex |
2021-05-26 |
73% |
2021-06-29 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/03/2021 |
News Article |
Herpes Simplex Virus Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026) |